CSE Cross Shr Reg S

RNS Number:9463C
Cross Shore Acquisition Corporation
29 August 2007





Cross Shore Acquisition Corporation

29 August 2007



                       Result of Special General Meeting


Cross Shore Acquisition Corporation ("Cross Shore") announces that the first
four resolutions proposed at its adjourned Special General Meeting held on
Tuesday 28 August 2007 were duly passed. The resolutions approved, inter alia,
the reverse takeover of ReSearch Pharmaceutical Services, Inc. (the
"Acquisition") and the change of the Company's name to ReSearch Pharmaceutical
Services, Inc.

The fifth resolution, which sought shareholder approval for the waiver of the
requirement to obtain a determination of the value of the Exchange Shares, was
not passed. Consequently, in order to satisfy the necessary condition to the
Merger Agreement, the Board of Cross Shore will obtain the necessary valuation
as part of the completion process.

The Acquisition, including the satisfaction of the valuation opinion condition,
is expected to be completed by close of business on Thursday 30 August 2007,
Eastern Standard Time.

Shareholders that elected to have an aggregate 8.4 million shares repurchased by
the Company (as described in the re-admission document dated 5 June 2007), will,
conditional upon completion of the Acquisition, have their shares repurchased
upon receipt by the Company of original share certificates.

Subject to completion of the Acquisition, the admission to trading on AIM of
Cross Shore's existing shares and warrants will be cancelled and an application
has been made for up to 42,003,422 shares and up to 2,986,667 warrants to be
re-admitted to trading on AIM. The cancellation and re-admission to trading of
both the shares and warrants is expected to become effective at 8.00 a.m. on 31
August 2007, as is the Company's change of name. Until that time, trading in
Cross Shore shares and warrants has been suspended with immediate effect.

Following the repurchase of shares, the cancellation of 3,000,001 Founder Shares
and the completion of both the warrant tender offer and the revised Sunrise
tender offer, 33,506,377 shares and 1,414,694 warrants will be in issue. It is
anticipated that these steps will be completed shortly after re-admission to
AIM.

In connection with the Acquisition, Pangaea One Acquisition Holdings I, LLC, an
affiliate of Cartesian Capital Group, LLC, has now agreed to acquire
approximately 10.7 million Cross Shore shares, including those that will result
from conversion of warrants under the warrant tender offer and including certain
shares to be acquired from the Founding Shareholders. Following completion of
these purchases and the steps outlined in the paragraph above, Pangaea will hold
approximately 32.8% of the outstanding share capital of the Company.

From 31 August 2007, Cross Shore's shares and warrants are expected to trade
under the symbols RPSE and RPSW respectively.




ENQUIRIES:

Cross Shore                                 +1 843 597 4760
Dennis Smith

ReSearch Pharmaceutical Services            +1 215 540 0700
Dan Perlman

Arbuthnot Securities Limited                +44 207 012 2000
Nominated Adviser and UK Broker
James Steel / Guy Blakeney


Arbuthnot Securities Limited, which is authorised and regulated in the United
Kingdom by the Financial Services Authority, is acting as nominated adviser and
UK broker to the Company in connection with Re-admission. Its responsibilities
as the Company's nominated adviser under the AIM Rules are owed solely to the
London Stock Exchange and are not owed to the Company or to any Director or
Proposed Director or to any other person.

Arbuthnot Securities Limited is acting exclusively for the Company and for no
one else and will not be responsible to anyone other than the Company for
providing the protections afforded to their clients or for providing advice in
relation to the contents of this announcement or the Re-admission. No
representation or warranty, express or implied, is made by Arbuthnot Securities
Limited as to the contents of this announcement. The information contained in
this announcement is not intended to inform or be relied upon by any subsequent
purchasers of Cross Shore Shares or Warrants (whether on or off exchange) and
accordingly no duty of care is accepted in relation to them.

The Directors and Proposed Directors of Cross Shore Acquisition Corporation
accept responsibility, individually and collectively, for the information
contained in this announcement and for compliance with the AIM Rules. To the
best of the knowledge and belief of the Directors and Proposed Directors, who
have taken all reasonable care to ensure that such is the case, the information
contained in this announcement is in accordance with the facts and does not omit
anything likely to affect the import of such information.


END




                      This information is provided by RNS
            The company news service from the London Stock Exchange

END
REGSEEFLUSWSESA

Cross Shore Acquisition (LSE:CSE)
Historical Stock Chart
From May 2024 to Jun 2024

Cross Shore Acquisition (LSE:CSE)
Historical Stock Chart
From Jun 2023 to Jun 2024